Drug Profile


Alternative Names: GX-I7; IL-7-hyFc; Interleukin-7-hybrid-Fc-recombinant-protein

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genexine
  • Class Antineoplastics; Antivirals; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin 7 receptor agonists; Lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cervical intraepithelial neoplasia; Human papillomavirus infections; Leucopenia
  • Preclinical Solid tumours

Most Recent Events

  • 30 May 2017 Phase-I clinical trials in Cervical intraepithelial neoplasia (Combination therapy) in South Korea (Vaginal) (NCT03206138)
  • 10 Feb 2017 Phase-I clinical trials in Human papillomavirus infections in South Korea (Vaginal) (NCT03144934)
  • 01 Jul 2016 Phase-I clinical trials in Human papillomavirus infections in South Korea (SC) (Genexine pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top